Obesity ... the final frontier. These are the voyages of the drug companies. Their mission: to help patients shed the pounds, to boldly go where no company has successfully gone before.
Unfortunately, two more drugs got assimilated by the Borg on Wednesday.
Farther back in the drug development process, Pfizer
The two companies join Merck
You'd think the news that three large pharmaceutical companies were abandoning the market would help smaller companies developing anti-obesity drugs like Arena's
The anti-obesity market may be a potential supernova for a drugmaker's revenue, but for now, it remains a black hole sucking up drugs and making pipelines thinner.
Pfizer and Glaxo are Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is an Inside Value selection. The Fool owns shares of Pfizer. The Fool has a disclosure policy.